Merck's Major US Expansion

In a significant move to bolster its pharmaceutical production capabilities, Merck & Co. Inc. has announced a staggering $1 billion investment in a new facility located in Delaware. This strategic expansion underscores the company's commitment to enhancing its drug manufacturing infrastructure within the United States.

Boosting Cancer Treatment and Employment

The new facility is set to revolutionize the production of Merck's flagship cancer treatment, Keytruda, introducing an injectable version by 2030. Beyond advancing healthcare solutions, this initiative is expected to generate 4,500 new jobs, marking a substantial boost to the local economy.

Aligning with National Drug Production Goals

Amid escalating discussions on drug tariffs, Merck's investment reflects a broader trend among pharmaceutical giants like Johnson & Johnson, Eli Lilly, and Roche, who are also amplifying their US manufacturing presence. "Our strategy ensures that US healthcare needs are met through domestic production, aligning with the current administration's objectives," stated Rob Davis, Merck's Chief Executive.